prikaz prve stranice dokumenta The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
  Download
PDF 764.27 KB
Scientific paper - Preliminary note / Short communication
The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
Diabetology and Metabolic Syndrome, 10 (2018), 16; 1-5. https://doi.org/10.1186/s13098-018-0321-x
Božek, Tomislav; Bilić Ćurčić, Ines; Cigrovski Berković, Maja; Gradišer, Marina; Kurir Tićinović, Tina; Klobučar-Majanović, Sanja; Marušić, Srećko

Cite this document

Božek, T., Bilić Ćurčić, I., Cigrovski Berković, M., Gradišer, M., Kurir Tićinović, T., Klobučar Majanović, S. & Marušić, S. (2018). The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study. Diabetology and Metabolic Syndrome, 10. (16), 1-5. doi: 10.1186/s13098-018-0321-x

Božek, Tomislav, et al. "The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study." Diabetology and Metabolic Syndrome, vol. 10, no. 16, 2018, pp. 1-5. https://doi.org/10.1186/s13098-018-0321-x

Božek, Tomislav, Ines Bilić Ćurčić, Maja Cigrovski Berković, Marina Gradišer, Tina Kurir Tićinović, Sanja Klobučar Majanović and Srećko Marušić. "The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study." Diabetology and Metabolic Syndrome 10, no. 16 (2018): 1-5. https://doi.org/10.1186/s13098-018-0321-x

Božek, T., et al. (2018) 'The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study', Diabetology and Metabolic Syndrome, 10(16), pp. 1-5. doi: 10.1186/s13098-018-0321-x

Božek T, Bilić Ćurčić I, Cigrovski Berković M, Gradišer M, Kurir Tićinović T, Klobučar Majanović S, and sur.. The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study. Diabetology and Metabolic Syndrome [Internet]. 2018 [cited 2025 January 01];10(16):1-5. doi: 10.1186/s13098-018-0321-x

T. Božek, et al., "The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study", Diabetology and Metabolic Syndrome, vol. 10, no. 16, pp. 1-5, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:945013. [Accessed: 01 January 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
AuthorTomislav Božek
AuthorInes Bilić Ćurčić
AuthorMaja Cigrovski Berković
AuthorMarina Gradišer
AuthorTina Kurir Tićinović
AuthorSanja Klobučar-Majanović
AuthorSrećko Marušić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
INTRODUCTION: This observational study aimed to assess the effectiveness of lixisenatide as add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes. METHODS: Patients with diabetes type 2, prescribed with lixisenatide and basal insulin were divided in three groups (premixed insulin, basal bolus insulin and basal oral therapy (BOT). Difference in mean change in HbA1c, body mass index, total insulin doses, fasting blood glucose (FPG) and prandial blood glucose (PPG) were assessed after 3-6-months of follow-up. RESULTS: The primary outcomes were assessed in 111 patients. Lixisenatide added to basal insulin, reduced HbA1c and body weight significantly in all three groups of patients (p < 0.001 for all), with the most prominent reduction in the basal bolus group of patients which had the highest baseline HbA1c compared to premix and BOT treatment groups. Regarding a difference in total insulin dose the reduction was statistically significant in the basal bolus (p = 0.006) and premix group (p < 0.001). FPG and PPG were also significantly reduced over time in all three groups (p < 0.001 for all). A composite outcome (reduction of HbA1c below 7% (53 mmol/mol) with any weight loss) was achieved in 27% of total patients included in the study, reduction of HbA1c below 7% was observed in 30% of patients, while 90% of patients experienced weight reduction. CONCLUSION: These results indicate that lixisenatide add on basal insulin treatment (BIT) can improve glycemic control in a population with long- standing type 2 diabetes and previously uncontrolled on other insulin therapy.
Keywords (english)
Languageenglish
Publication typeScientific paper - Preliminary note / Short communication
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDiabetology and Metabolic Syndrome
Numberingvol. 10, no. 16, pp. 1-5
p-ISSN1758-5996
DOIhttps://doi.org/10.1186/s13098-018-0321-x
URN:NBNurn:nbn:hr:184:945013
Publication2018
Document URLhttp://bib.irb.hr/932480
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-03-10 17:35:17